| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/31/2001 | EP1071680A1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors |
| 01/31/2001 | EP1071658A2 Btk inhibitors and methods for their identification and use |
| 01/31/2001 | EP1071463A1 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 01/31/2001 | EP1071462A1 Methods and compositions using norastemizole in combination with leukotriene inhibitors |
| 01/31/2001 | EP1071459A1 Methods to provoke anti-cancer immune responses |
| 01/31/2001 | EP1071458A1 Humanized antibody and uses thereof |
| 01/31/2001 | EP1071457A1 Polymer particle vaccine delivery system |
| 01/31/2001 | EP1071456A1 Vaccines with an ltb adjuvant |
| 01/31/2001 | EP1071452A1 Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof |
| 01/31/2001 | EP1071451A2 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 01/31/2001 | EP1071449A2 Antagonists of the inflammatory mediator oncostatin m (osm) |
| 01/31/2001 | EP1071443A1 Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein bind to mhc class i and mhc class ii molecules, and uses thereof |
| 01/31/2001 | EP1071440A1 Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga |
| 01/31/2001 | EP1071433A2 Pharmaceutical composition |
| 01/31/2001 | EP1071423A1 Antagonists of gonadotropin releasing hormone |
| 01/31/2001 | EP1071414A1 Compounds and methods for treating mitochondria-associated diseases |
| 01/31/2001 | EP1071411A1 Topical immunostimulation to induce langerhans cell migration |
| 01/31/2001 | EP1071333A1 Induction of immunity against tumor self-antigens |
| 01/31/2001 | EP1071329A1 Methods and compositions for treatment of aids-associated kaposi's sarcoma |
| 01/31/2001 | EP1071327A1 Autoantigenic fragments, methods and assays |
| 01/31/2001 | EP0746320B1 Hiv protease inhibitors and intermediates |
| 01/31/2001 | CN1282372A Mammalian sytokine-like polypeptide-10 |
| 01/31/2001 | CN1282371A Ac (DNA encoding C6 beta-chemokine leukotactin-1 (Lkn-1) isolated from human |
| 01/31/2001 | CN1282337A Cyclopeptide derivatives with integrin inhibitor properties |
| 01/31/2001 | CN1282255A IFNAR2/I FN complex |
| 01/31/2001 | CN1282254A Compositions and methods for regulating phagocytosis and ICAM-1 expression |
| 01/31/2001 | CN1282253A Small peptides and method for treatment of asthma and inflammation |
| 01/31/2001 | CN1282223A Fat blend |
| 01/31/2001 | CN1061261C Ginseng-Chinese angelica liquor |
| 01/31/2001 | CN1061239C Specific curing agent for AIDS |
| 01/30/2001 | US6180791 Synthesis of 8-substituted xanthines |
| 01/30/2001 | US6180773 The cc type chemokines belong to a family of polypeptides which have proven to be mediators of immune reactions, and which have antiviral activity with respect to hiv |
| 01/30/2001 | US6180771 Given nucleotide sequence; useful for pharmaceutical administration or methods of diagnosing sensitivity to house dust mites |
| 01/30/2001 | US6180675 IL-8 receptor antagonists |
| 01/30/2001 | US6180662 Mixture of cinnamic acid, antioxidant, enzyme, microbiocides and viricides |
| 01/30/2001 | US6180643 Antagonist of interleukins, tumor necrosis factor |
| 01/30/2001 | US6180639 Therapy for human immunodeficiency virus |
| 01/30/2001 | US6180637 Therapy for parkinson, alzheimer disease |
| 01/30/2001 | US6180635 Novel thieno(2,3-d)pyrimidinediones which exhibit pharmacological activity, in particular immunosuppressive activity; treating allograft rejection |
| 01/30/2001 | US6180611 Inhibitors of matrix metalloproteinases and tumor necrosis factor |
| 01/30/2001 | US6180403 Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression |
| 01/30/2001 | US6180377 Humanized antibodies |
| 01/30/2001 | US6180370 Preparing preferential antibodies; generating nucleotide sequences coding preferential antibodies, expressing nucleotide sequences in transformed cell and recovering preferential antibodies |
| 01/30/2001 | US6180369 Varicella-zoster virus antigen |
| 01/30/2001 | US6180368 Ryegrass pollen allergen |
| 01/30/2001 | US6180353 Nucleotide sequences associated with suppression of transcription binding protein associated with apoptosis; for the treatment and prevention defects associated with apoptosis |
| 01/30/2001 | US6180111 Vaccine delivery system |
| 01/30/2001 | US6180104 Can be used such as nucleotide probes, combining with foreign dna sequences to produce novel t-cell receptors, which can be used in an analogous manner as antibodies, or constructs can be provided which provide for extrachromosomal elements |
| 01/30/2001 | US6180097 For treatment of solid tumors, including their metastases, without radiation, surgery or standard chemotherapeutic by using superantigens, including staphyloccocal enterotoxins b and c, to stimulate tumor draining lymph node cells |
| 01/30/2001 | CA2191352C Quinoline derivatives as tachykinin nk3 receptor antagonists |
| 01/30/2001 | CA2022610C Human gp130 protein |
| 01/25/2001 | WO2001006756A2 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 01/25/2001 | WO2001006018A1 Antisense modulation of map kinase kinase 6 expression |
| 01/25/2001 | WO2001006015A1 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 01/25/2001 | WO2001005990A1 Structural protein of adeno-associated virus with modified antigenicity, its production and its use |
| 01/25/2001 | WO2001005983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | WO2001005974A2 The il-1l1 gene and polypeptide products |
| 01/25/2001 | WO2001005972A1 Compositions and methods for the treatment of immune related diseases |
| 01/25/2001 | WO2001005970A2 Gtp-binding protein associated factors |
| 01/25/2001 | WO2001005969A2 Electron transfer proteins |
| 01/25/2001 | WO2001005967A1 Splice variants of cd40-receptor |
| 01/25/2001 | WO2001005834A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | WO2001005823A2 Tryptase inhibitor |
| 01/25/2001 | WO2001005802A1 Antisense modulation of fadd expression |
| 01/25/2001 | WO2001005792A1 Anti-inflammatory oxo derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use |
| 01/25/2001 | WO2001005776A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 01/25/2001 | WO2001005774A1 Heteroaromatic ring compounds |
| 01/25/2001 | WO2001005772A1 Pyrazinones, compositions containing such compounds |
| 01/25/2001 | WO2001005770A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 01/25/2001 | WO2001005768A1 Tricyclic compounds bearing acyloxymethoxycarbonyl pendants |
| 01/25/2001 | WO2001005751A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 01/25/2001 | WO2001005750A1 p-TERPHENYL COMPOUNDS BEARING ACYLOXYMETHOXYCARBONYL SIDE CHAINS |
| 01/25/2001 | WO2001005749A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 01/25/2001 | WO2001005746A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 01/25/2001 | WO2001005745A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 01/25/2001 | WO2001005744A1 Novel aminobenzophenones |
| 01/25/2001 | WO2001005743A1 3-amino-2-benzyl-1-phenyl-propane derivatives |
| 01/25/2001 | WO2001005480A2 Chemokine binding protein of gammaherpesvirus 68 and methods of use therefor |
| 01/25/2001 | WO2001005436A1 Method for producing antibodies in egg yolk and use of resulting antibodies |
| 01/25/2001 | WO2001005423A1 Use of vasoactive intestinal peptide (vip) for modulating the development of a specific immune response |
| 01/25/2001 | WO2001005422A2 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | WO2001005420A1 Small peptides and methods for downregulation of ige |
| 01/25/2001 | WO2001005414A1 Algae protein polysaccharide extraction and use thereof |
| 01/25/2001 | WO2001005406A1 Glycyrrhizin preparations for transmucosal absorption |
| 01/25/2001 | WO2001005394A1 Agents inhibiting chronic rejection reactions after organ transplantation |
| 01/25/2001 | WO2001005357A1 Two-component composition for cosmetic or pharmaceutical use |
| 01/25/2001 | WO2000066111B1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions |
| 01/25/2001 | WO2000062805A8 A method of reversing thymic atrophy |
| 01/25/2001 | WO2000061171A3 Uses of mammalian ox2 protein and related reagents |
| 01/25/2001 | WO2000060080A3 Molecules of the immune system |
| 01/25/2001 | WO2000058473A3 Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| 01/25/2001 | WO2000056360A3 Vaccine against antigens from bacteriae |
| 01/25/2001 | WO2000056356A3 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs) |
| 01/25/2001 | WO2000054815A3 Expression of dna or proteins in c. elegans |
| 01/25/2001 | WO2000053219A3 Compositions and methods for treating cancer and hyperproliferative disorders |
| 01/25/2001 | WO2000044740A3 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 01/25/2001 | DE19933421A1 2-Benzyl-3-dimethylamino-1-phenyl-propanderi- vate 2-benzyl-3-dimethylamino-1-phenyl-propanderi- derivatives |
| 01/25/2001 | CA2381961A1 Splice variants of cd40-receptor |
| 01/25/2001 | CA2381327A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | CA2379983A1 Dsp-11 dual-specificity map kinase phosphatase |